Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis.


BACKGROUND The benefit of the combination of infliximab (IFX) and immunosuppressant (IS) therapy is debated in ulcerative colitis (UC). AIMS To determine whether the combination of IFX and IS therapy is more effective than infliximab alone for active UC regardless of prior IS use. METHODS We identified all controlled trials including patients with… (More)
DOI: 10.1111/apt.13102


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics